Further studies suggest that these macrophages can be categorized into two groups: tumor-resident macrophages (CD206+YM-1+F4/80+Gr1-) and tumor-associated macrophages (CD206-YM-1- F4/80+Gr1-), with the former as the major tumor macrophage population that respond to anti-IL-25 antibody treatment. This evidence concerns the gene MRC1 and neoplasm.